Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

TVGN

Tevogen Bio Holdings Inc

Oct 31 • 04:00PM ET

2.53

Dollar change +0.07
Percentage change 2.85	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA CRSP GILD FATE EDIT ALLO IMTX ADAP PSTX BLUE

| Held by: IWO IWC VTWO RSSL UWM VTWG URTY VTWV ITWO HDG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.37	Insider Own	87.13%	Shs Outstand	170.65M	Perf Week	-1.17%
Market Cap	431.74M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.72%	Shs Float	21.96M	Perf Month	723.30%
Income	3.32M	PEG	-	EPS next Q	-	Inst Own	3.82%	Short Float	14.53%	Perf Quarter	350.98%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-16.24%	Short Ratio	0.22	Perf Half Y	156.54%
Book/sh	-0.06	P/B	-	EPS next Y	-	ROA	22.57%	Short Interest	3.19M	Perf Year	-76.62%
Cash/sh	0.01	P/C	378.72	EPS next 5Y	-	ROE	268.90%	52W Range	0.26 - 21.09	Perf YTD	-77.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-88.00%	Beta	0.31
Dividend TTM	-	Quick Ratio	0.23	Sales past 5Y	0.00%	Gross Margin	-	52W Low	889.83%	ATR (14)	0.44
Dividend Ex-Date	-	Current Ratio	0.23	EPS Y/Y TTM	-129.97%	Oper. Margin	0.00%	RSI (14)	69.43	Volatility	19.53% 32.90%
Employees	17	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	4.20
Option/Short	No / No	LT Debt/Eq	-	EPS Q/Q	-220.33%	Payout	-	Rel Volume	0.38	Prev Close	2.46
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	14.60M	Price	2.53
SMA20	67.26%	SMA50	189.49%	SMA200	4.20%	Trades		Volume	5,494,048	Change	2.85%

Today 10:54AM	Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs (GlobeNewswire)
Oct-29-24 03:28PM	Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company (GlobeNewswire) -6.93%
02:38PM	Alpha Capital Appointed as Exclusive Financial Advisor to CD8 Technology to Secure Funding Up To $50 Million (GlobeNewswire)
12:43PM	Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity (GlobeNewswire)
Oct-25-24 05:34PM	Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas (GlobeNewswire) +19.14% -10.16%
08:35AM	Loading…
Oct-23-24 08:35AM	Tevogen Bio's Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development (GlobeNewswire) +54.04%
Oct-22-24 02:30PM	Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week (GlobeNewswire) -10.56%
Oct-21-24 03:58PM	Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion (GlobeNewswire)
01:56PM	Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days (GlobeNewswire)
Oct-18-24 10:46PM	Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company's Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days (GlobeNewswire) +24.64%
Oct-17-24 09:32AM	Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow (GlobeNewswire) +32.69%
07:54AM	Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion (GlobeNewswire)
Oct-16-24 04:30PM	Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality (GlobeNewswire) -24.09%
Oct-15-24 02:30PM	Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions (GlobeNewswire) +25.69%
11:36AM	Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company's Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use (GlobeNewswire)
06:43PM	Loading…
Oct-14-24 06:43PM	Tevogen CEO Reaffirms the Company's Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections (GlobeNewswire) +187.14%
11:39AM	Leaders in The News: BigBear.ai, Luminar, New World Solutions, Tevogen Bio (News Direct)
Oct-11-24 03:59PM	Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024 (GlobeNewswire) +18.51%
12:12PM	Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID (GlobeNewswire)
Oct-08-24 02:40PM	Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation (GlobeNewswire)
Sep-24-24 11:09AM	Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation (GlobeNewswire)
Aug-22-24 09:00AM	Tevogen Bio Secures $6 Million Series C Preferred Stock Investment (GlobeNewswire)
Aug-15-24 12:17PM	CORRECTION - Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares (GlobeNewswire)
09:00AM	Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares (GlobeNewswire)
Aug-14-24 09:00AM	Tevogen Bio's Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health (GlobeNewswire) +6.63%
Aug-09-24 11:00AM	Tevogen Bio's Founding CEO, Ryan Saadi, Expresses Conviction in Company's Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities (GlobeNewswire)
Jul-11-24 12:21PM	Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback (GlobeNewswire)
Jul-10-24 08:05AM	Tevogen Bio's R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian (GlobeNewswire)
Jul-08-24 04:07PM	Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility (GlobeNewswire)
Jun-26-24 12:46PM	Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities (GlobeNewswire) +7.45%
08:05AM	Loading…
Jun-25-24 08:05AM	Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances (GlobeNewswire) -10.35%
Jun-18-24 03:17PM	Tevogen.AI Head Discusses Company's Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference (GlobeNewswire) -8.31%
Jun-12-24 03:45PM	Tevogen Bio Set to Join Russell 3000 Index (GlobeNewswire)
Jun-11-24 03:30PM	Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts (GlobeNewswire) +6.50%
Jun-07-24 03:32PM	CORRECTION Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event (GlobeNewswire) -7.23%
Jun-06-24 06:14PM	Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event (GlobeNewswire) +14.90%
03:52PM	Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2 (GlobeNewswire)
May-30-24 06:52PM	TVGN Stock Earnings: Tevogen Bio Holdings Reported Results for Q1 2024 (InvestorPlace)
May-29-24 08:00AM	Tevogen Bio Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-16-24 02:00PM	Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives (GlobeNewswire) -8.20%
May-13-24 07:52AM	Why Is Tevogen Bio (TVGN) Stock Up 54% Today? (InvestorPlace)
07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
May-10-24 05:40PM	Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives (GlobeNewswire)
May-01-24 08:05AM	Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives (GlobeNewswire)
Apr-26-24 09:23AM	Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments (GlobeNewswire) +17.65%
Apr-11-24 08:05AM	Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers (GlobeNewswire)
Apr-03-24 08:05AM	Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development (GlobeNewswire) -11.19%
Mar-28-24 08:05AM	Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price (GlobeNewswire) +8.05%
Mar-27-24 09:20AM	Tevogen Bio Announces Series A-1 Preferred Stock Investment (GlobeNewswire) -10.65%
Mar-20-24 07:00AM	Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant (Business Wire)
Mar-05-24 08:00AM	Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita (Business Wire)
Feb-27-24 04:39PM	Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI (Business Wire)
Feb-21-24 07:00AM	Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment (Business Wire)
Feb-17-24 12:17AM	Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market (Business Wire)
Feb-15-24 09:25AM	Tevogen Bio Announces $8 Million Equity Investment (Business Wire) +121.73%
Feb-14-24 03:55PM	Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN (GlobeNewswire)
Feb-01-24 08:15AM	Semper Paratus Acquisition Corporation's Shareholders Approve Business Combination with Tevogen Bio (GlobeNewswire) -8.73%
Jan-24-24 04:05PM	Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq (GlobeNewswire)
Jan-05-24 08:55AM	Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination (GlobeNewswire)
Sep-29-23 08:50AM	Semper Paratus Acquisition Corporation Regains Compliance with Certain Nasdaq Listing Requirement (GlobeNewswire)
Sep-14-23 05:30PM	Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc (GlobeNewswire)
Jun-29-23 08:05AM	Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation (GlobeNewswire)

Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company. It develops off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company was founded on February 14, 2024 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flomenberg Neal	See Remarks	Oct 17 '24	Sale	1.62	1,078,600	1,747,332	4,254,302	Oct 18 09:57 PM
Desai Kirti	Chief Financial Officer	Jun 12 '24	Buy	0.82	3,000	2,460	9,699,186	Jun 13 04:30 PM
Saadi Ryan H.	Chief Executive Officer	Jun 05 '24	Buy	0.77	2,607	2,000	118,252,659	Jun 07 04:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TVGN

Tevogen Bio Holdings Inc

Upgrade your FINVIZ experience